Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insulet (PODD) reports record-breaking Q4 earnings, eyes international expansion

Insulet's Q4 2022 earnings call highlighted exceptional revenue growth, strong customer adoption of Omnipod 5, and a focus on customer-centric innovation. While facing challenges with device corrections and FDA approval timelines, the company remains optimistic about revenue growth, margin improvement, and strategic investments in innovation and expansion.

Insulet reports robust Q1 growth, eyes global expansion opportunities

Insulet's Q1 2023 showcased strong financials, driven by Omnipod 5 success and U.S. market growth.
Optimism for future growth, market leadership, and expansion into underpenetrated global markets.
Challenges include declining drug delivery business and the need for continued innovation and market penetration strategies.

Insulet reports robust Q2 earnings, eyes European expansion and innovation

Insulet's Q2 performance exceeded expectations, driven by strong revenue growth and the success of Omnipod 5, showcasing the company's market strength and innovation.
While facing challenges such as inventory management and uncertainties around new products like Omnipod GO, Insulet remains optimistic about its growth trajectory and international expansion.
The company's strategic focus on consumer needs, continuous innovation, and expansion into new markets position it well for sustained leadership and revenue growth in the diabetes management sector.

Insulet excels in Q3 with Omnipod 5 driving growth

Insulet's Q3 performance was robust, driven by Omnipod 5 success.
Confidence in growth outlook, financial strength, and market positioning.
Challenges include competition, timing guidance, and market penetration.
Opportunities lie in basal market expansion and international growth potential.

Insulet (PODD) reports stellar Q4 results and eyes global expansion

Insulet's Q4 2023 performance was robust, driven by strong revenue growth and milestone achievements.
The company's strengths lie in its focus on innovation, market positioning, and strategic partnerships.
Challenges include optimizing resource allocation, reimbursement negotiations, and meeting high demand.
Opportunities for Insulet include expanding digital capabilities, driving innovation, and capturing market growth.

Insulet (PODD) reports record Q3 revenue and outlines growth strategies

Insulet's Q3 performance exceeded expectations with strong revenue and margin growth.
The company's focus on expanding Omnipod 5 platform and international growth is key.
Challenges include maintaining growth rates and sustaining pricing benefits.
Opportunities lie in accelerating international expansion and enhancing customer experience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom

Intuitive Surgical

Vertex Pharmaceuticals

Vertex, Intuitive Surgical, Dexcom and Insulet are in buy range ahead of the J.P. Morgan Healthcare Conference.

Vertex, Dexcom, Insulet, Intuitive Surgical In Buy Range Before Healthcare Conference

The diabetes-management space is poised to continue to grow.

Why Diabetes Stocks DexCom and Insulet Soared 83% and 116%, Respectively, in 2019

Seagen

These two stocks don't appear to be slowing down anytime soon.

2 Healthcare Stocks That Doubled in 2019 and Can Still Go Higher

The full-market commercial launch of Insulet's (PODD) Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System is encouraging.

Insulet Rides on Innovation, Omnipod's Wider Market Appeal

Generac Holdings

TransDigm

The 2010s were good to shares of this diabetes specialist, aerospace company, and backup generator maker.

3 Under-the-Radar Top Stocks That Have Increased More Than 10 Times Over the Decade

Insulet (PODD) reported earnings 30 days ago. What's next for the stock?

Why Is Insulet (PODD) Up 14.3% Since Last Earnings Report?

Shares of the leader in tubeless insulin pump technology have gained a whopping 129% so far in 2019.

Why Diabetes Stock Insulet Soared 28% in November

Insulet (NASDAQ: PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, has seen its stock price rally by close to 17% over the last month. There have been multiple factors driving the rally.

Why Is Insulet Stock Up More Than 15% Over The Last Month?

Guardant Health Inc

Guardant, Dexcom, and Insulet nailed their quarters and have massive room to grow in the long run, too.

3 Medtech Earnings Winners

Insulet (PODD) has been gaining from several positive developments recently.

Insulet (PODD) Hits a 52-Week High: What's Driving the Stock?

NVIDIA

Shares of this AI leader and diabetes specialist seem to have long runways for growth.

2 Top Growth Stocks Set Annual Highs on Tuesday -- Are They Buys?

Insulet (PODD) achieves several milestones with respect to strengthening Omnipod's market access.

Insulet Rides on Omnipod's Wider Market Reach, New Products

Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.

Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View

The maker of tubeless insulin pumps continues to deliver sales growth ahead of industry watchers' outlook.

Why Insulet's Shares Rose 10.6% Higher Today

In the third quarter, the diabetes management specialist delivered revenue growth of 27% year over year.

Diabetes Stock Insulet Pops on Earnings Beat and Guidance Raise

Insulet Corporation (PODD) CEO Shacey Petrovic on Q3 2019 Results - Earnings Call Transcript

Insulet (PODD) delivered earnings and revenue surprises of 200.00% and 7.37%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Insulet (PODD) Surpasses Q3 Earnings and Revenue Estimates

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Henry Schein

Zimmer Biomet Hlds

Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.

Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More

GW Pharmaceuticals

MacroGenics

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

3 'Medical Product' Stocks Likely to Beat This Earnings Season

Insulet (PODD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Insulet (PODD)

After last month's pullback, shares of the leader in tubeless insulin pump technology are up 85% in 2019.

Why Diabetes Stock Insulet Dropped 12% in October

American Water Works

Looking for stocks for the long term? You might want to consider buying this artificial intelligence stock, diabetes stock, and dividend-paying utility stock.

3 Stocks - Poised for Huge Growth Over the Next Decade

Insulet’s Omnipod has low or zero up-front costs and better reimbursements.

Insulet: Low-Cost Pricing And Promising Pipeline To Drive Sales

FDA's approval will enable Insulet (PODD) to boost its insulin management business.

Insulet Receives FDA Approval for ACE Pump Implementation

The Massachusetts-based medical device company Insulet Corporation (NASDAQ: PODD) said Monday that the FDA has approved its Alternate Controller Enabled Infusion, or ACE, pump.

News for Insulet Stock (PODD)